-
2022-501606-35-01
11
2024-02-21
Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peri
-
2023-505486-92-00
4
2024-02-09
Small bowel adenocarcinoma
-
2022-503126-12-01
5
2024-01-05
Hypoparathyroidism
-
2022-500293-34-01
7
2023-12-28
Bronchopulmonary Dysplasia
-
2022-502739-20-00
5
2023-11-16
Active Idiopathic Inflammatory Myopathies (Including Dermatomyositis o
-
2022-501788-41-00
5
2023-11-14
Ulcerative Colitis
-
2022-502548-12-00
5
2023-09-28
marginal zone lymphoma
-
2023-503290-38-00
4
2023-09-05
Bronchiectasis
-
2022-501709-11-00
5
2023-06-06
Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
-
2022-501427-24-00
4
2023-04-25
Nonadvanced Systemic Mastocytosis
-
2022-500479-29-00
10
2023-03-28
International Prognostic Scoring System-Revised (IPSS-R) Low - or Inte
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2023-507379-23-00
10
2022-08-18
Generalized Myasthenia Gravis
-
2023-506145-38-00
3
2021-05-11
Treatment of participants with MF, MDS, ET, or MDS/MPN
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2024-518223-29-00
4
2020-03-10
Advanced or metastatic untreated EGFR mutation positive NSCLC
-
2023-506471-10-00
5
2019-10-04
Secondary hyperparathyroidism (SHPT) in pediatric patients with chroni
-
2024-519246-75-01
4
2026-06-15
Patients With Muscle-Invasive Bladder Cancer
-
2025-523428-39-00
4
2026-06-05
Mantle Cell Lymphoma
-
2025-523704-77-00
4
2026-06-04
Geographic atrophy secondary to age-related macular degeneration
-
2025-521587-35-00
5
2026-06-03
Metastatic colorectal cancer
-
2025-523544-12-00
5
2026-06-02
Myelodysplastic neoplasms/syndromes (MDS)
-
2025-523461-17-01
5
2026-06-01
LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
-
2025-521976-80-00
4
2026-05-28
Relapsed or Refractory
Multiple Myeloma (RRMM)